IL178329A0 - Compositions and methods for modulating vascular development - Google Patents

Compositions and methods for modulating vascular development

Info

Publication number
IL178329A0
IL178329A0 IL178329A IL17832906A IL178329A0 IL 178329 A0 IL178329 A0 IL 178329A0 IL 178329 A IL178329 A IL 178329A IL 17832906 A IL17832906 A IL 17832906A IL 178329 A0 IL178329 A0 IL 178329A0
Authority
IL
Israel
Prior art keywords
compositions
methods
vascular development
modulating vascular
modulating
Prior art date
Application number
IL178329A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL178329A0 publication Critical patent/IL178329A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL178329A 2004-04-14 2006-09-27 Compositions and methods for modulating vascular development IL178329A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56205404P 2004-04-14 2004-04-14
PCT/US2005/013658 WO2005117968A2 (en) 2004-04-14 2005-04-14 Compositions and methods comprising an egfl7 antagonist for modulating vascular development

Publications (1)

Publication Number Publication Date
IL178329A0 true IL178329A0 (en) 2007-02-11

Family

ID=35355481

Family Applications (2)

Application Number Title Priority Date Filing Date
IL178329A IL178329A0 (en) 2004-04-14 2006-09-27 Compositions and methods for modulating vascular development
IL226899A IL226899A0 (en) 2004-04-14 2013-06-13 Preparations and methods for modulating development@כלי@דם

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL226899A IL226899A0 (en) 2004-04-14 2013-06-13 Preparations and methods for modulating development@כלי@דם

Country Status (14)

Country Link
US (3) US20070031437A1 (https=)
EP (1) EP1734998A2 (https=)
JP (3) JP5599136B2 (https=)
KR (1) KR101227817B1 (https=)
CN (2) CN1997394B (https=)
AU (1) AU2005249377A1 (https=)
BR (1) BRPI0509420A (https=)
CA (1) CA2563445C (https=)
IL (2) IL178329A0 (https=)
MX (1) MXPA06011851A (https=)
NZ (1) NZ550110A (https=)
RU (3) RU2365382C2 (https=)
WO (1) WO2005117968A2 (https=)
ZA (1) ZA200608615B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06011851A (es) * 2004-04-14 2006-12-14 Genentech Inc Composiciones y metodos para moduilar el desarrollo vascular.
AR059851A1 (es) * 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
US8541559B2 (en) 2006-06-12 2013-09-24 Cytos Biotechnology Ag Process for producing aggregated oligonucleotides
WO2008010986A2 (en) * 2006-07-17 2008-01-24 The Board Of Trustees Of The Leland Stanford Junior University Methods of modulating angiogenesis
WO2008130719A1 (en) * 2007-04-24 2008-10-30 University Of Louisville Therapeutic beta-glucan combinations
JP2009005584A (ja) * 2007-06-26 2009-01-15 Miyazaki Prefecture ゲル化剤、凍結保存剤、細胞保存用容器、細胞の凍結保存方法、細胞の融解方法、哺乳動物の細胞
EP2235189A1 (en) * 2008-01-14 2010-10-06 Genentech, Inc. Methods for inhibiting angiogenesis using egfl8 antagonists
WO2010034155A1 (zh) * 2008-09-25 2010-04-01 中南大学湘雅医院 一种通过检测样品中eglf7来诊断肝细胞癌的试剂盒
PE20120902A1 (es) * 2009-05-08 2012-08-08 Genentech Inc Anticuerpos anti-egfl7 humanizados
RU2412251C1 (ru) * 2009-06-15 2011-02-20 Юрий Леонидович Дорохов Антитело против фактора роста эндотелия сосудов и способ продукции антитела в растении
AU2010273585B2 (en) * 2009-07-13 2015-04-23 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
BR112012013093A2 (pt) * 2009-12-21 2017-12-12 Genentech Inc ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável
WO2013061112A1 (en) 2011-10-24 2013-05-02 Centre National De La Recherche Scientifique Use of egfl7 modulators for promoting or inhibiting migration of immune cells across vascular endothelium
EP2831093A4 (en) * 2012-03-27 2015-11-04 London Health Sci Ct Res Inc EGFL7-targeting or binding polypeptides and methods for inhibiting angiogenesis
US20170007495A1 (en) * 2013-11-21 2017-01-12 Mfr Products, Inc. Therapeutic device to assist in myofascial release, and method of use
RU2729161C2 (ru) * 2014-10-23 2020-08-04 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
CN105543183B (zh) * 2016-01-08 2019-04-12 吴帆 人肝癌细胞Egfl8基因过表达慢病毒在制备治疗肝癌药物中的应用
US11702469B2 (en) 2017-04-24 2023-07-18 Ohio State Innovation Foundation Recombinant EGFL7, EGFL7 antibodies, and uses thereof
RU2678200C1 (ru) * 2018-07-27 2019-01-24 Федеральное государственное бюджетное научное учреждение "Иркутский научный центр хирургии и травматологии" Лекарственная пленка пролонгированного действия и способ её получения
DE212020000830U1 (de) 2020-07-28 2023-10-30 Limited Liability Company "Angiolife" Verwendung einer Kombination von Genen angiogener und neurotropher Faktoren
CN114410642B (zh) * 2021-12-31 2023-01-17 苏州大学 一种急性t淋巴细胞白血病药物靶点及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0248088A4 (en) * 1985-11-22 1988-05-03 Teijin Ltd VASCULARIZATION FACTOR AND MANUFACTURING.
EP0318488A4 (en) 1986-08-18 1990-02-26 Biota Scient Management STIMULATION OF ANGIOGENESIS AND PROMOTION OF ENDOTHELIALIZATION.
SK163598A3 (en) * 1996-05-31 1999-06-11 Scripps Research Inst Methods and compositions useful for inhibition of angiogenesis
WO2002000690A2 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2002008284A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000053752A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
AU737132B2 (en) * 1997-06-18 2001-08-09 Zymogenetics Inc. Mammalian neuro-growth factor like protein
US20030166907A1 (en) * 1997-06-18 2003-09-04 Zymogenetics, Inc. Mammalian neuro-growth factor like protein
US5972338A (en) 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US20030022293A1 (en) 1997-09-18 2003-01-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6974696B2 (en) 1997-10-17 2005-12-13 Genentech, Inc. PRO853 nucleic acids
US6391311B1 (en) 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
US20030069178A1 (en) 1997-10-17 2003-04-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7105640B2 (en) 1997-10-17 2006-09-12 Genentech, Inc. Anti-pro792 antibodies
US7196165B2 (en) 1997-10-17 2007-03-27 Genentech, Inc. PRO363 polypeptides
US20030039648A1 (en) 1998-09-16 2003-02-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
US7371836B2 (en) 1998-03-27 2008-05-13 Genentech, Inc. PRO526 nucleic acids
US7202338B2 (en) 1998-03-31 2007-04-10 Genentech, Inc. PRO731 polypeptides
US7166700B2 (en) 1998-04-01 2007-01-23 Genentech, Inc. PRO703 Polypeptides
US6962797B2 (en) 1998-04-15 2005-11-08 Genentech, Inc. Nucleic acids encoding PRO615
DE19817946A1 (de) 1998-04-17 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Uterus-Normalgewebe
AU3965799A (en) 1998-04-23 1999-11-08 Millennium Pharmaceuticals, Inc. Novel molecules of the t125-related protein family and uses thereof
US7067636B2 (en) 1998-05-06 2006-06-27 Genentech, Inc. Anti-pro 1017 antibodies
US7279553B2 (en) 1998-05-13 2007-10-09 Genentech, Inc. PRO1083 polypeptides
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US7019115B2 (en) 1998-05-22 2006-03-28 Genentech, Inc. Pro1017 polypeptides
US7220835B2 (en) 1998-07-30 2007-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001054477A2 (en) 2000-01-25 2001-08-02 Hyseq, Inc. Novel nucleic acids and polypeptides
CA2353797A1 (en) 1998-12-11 2000-06-15 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
US20030009013A1 (en) 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000058473A2 (en) 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'
WO2000063756A1 (en) 1999-04-16 2000-10-26 Fujikin Incorporated Parallel bypass type fluid feeding device, and method and device for controlling fluid variable type pressure system flow rate used for the device
US7214656B2 (en) 1999-04-28 2007-05-08 Genentech, Inc. PRO792 polypeptides
JP2003504021A (ja) 1999-07-02 2003-02-04 財団法人相模中央化学研究所 疎水性ドメインを有するヒトプロテイン並びにそれをコードするｄｎａ
US7589172B2 (en) 1999-07-20 2009-09-15 Genentech, Inc. PRO256 polypeptides
TWI265167B (en) 1999-11-29 2006-11-01 Akzo Nobel Nv 3-methylene steroid derivatives
US7193050B2 (en) 2000-02-18 2007-03-20 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7442765B2 (en) 2000-08-24 2008-10-28 Genentech, Inc. Secreted transmembrane polypeptides and nucleic acids encoding the same
US7265210B2 (en) 2000-09-15 2007-09-04 Genentech, Inc. Anti-PRO9821 antibodies
WO2002076486A2 (en) * 2001-02-05 2002-10-03 Innoventus Project Ab Histidine-rich glycoprotein
US20030224984A1 (en) * 2001-06-20 2003-12-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7164007B2 (en) 2001-06-20 2007-01-16 Genentech, Inc. Anti-PR020044 antibodies
FR2851249A1 (fr) * 2003-02-17 2004-08-20 Commissariat Energie Atomique Nouveau facteur soluble secrete par les cellules endotheliales des vaisseaux sanguins, capable d'inhiber le recrutement des cellules perivasculaires du type musculaire lisse et ses applications
MXPA06011851A (es) 2004-04-14 2006-12-14 Genentech Inc Composiciones y metodos para moduilar el desarrollo vascular.

Also Published As

Publication number Publication date
AU2005249377A1 (en) 2005-12-15
US8790646B2 (en) 2014-07-29
MXPA06011851A (es) 2006-12-14
JP5599136B2 (ja) 2014-10-01
EP1734998A2 (en) 2006-12-27
US20070031437A1 (en) 2007-02-08
RU2006140081A (ru) 2008-05-20
CN1997394A (zh) 2007-07-11
JP2007532685A (ja) 2007-11-15
WO2005117968A3 (en) 2006-06-08
RU2013146239A (ru) 2015-04-27
CA2563445A1 (en) 2005-12-15
CA2563445C (en) 2016-07-19
IL226899A0 (en) 2013-07-31
BRPI0509420A (pt) 2007-09-04
US20090297512A1 (en) 2009-12-03
CN1997394B (zh) 2012-11-28
CN102895663A (zh) 2013-01-30
KR101227817B1 (ko) 2013-01-29
JP2011241230A (ja) 2011-12-01
RU2365382C2 (ru) 2009-08-27
KR20070029687A (ko) 2007-03-14
WO2005117968A2 (en) 2005-12-15
JP2013256535A (ja) 2013-12-26
ZA200608615B (en) 2008-05-28
US20120003208A1 (en) 2012-01-05
NZ550110A (en) 2009-09-25
RU2009114508A (ru) 2010-10-27

Similar Documents

Publication Publication Date Title
IL226899A0 (en) Preparations and methods for modulating development@כלי@דם
IL194788A0 (en) Compositions and methods for modulating vascular development
IL185708A0 (en) Methods and compositions for modulating hyperstabilized c-met
GB0422525D0 (en) Dermatological compositions and methods
EP1711131A4 (en) FEMORO-PATELLAR PROSTHESIS
GB2434983B (en) Methods and compositions for wound healing
ZA200804026B (en) Compositions and methods for modulating hemostasis
ZA200700351B (en) Compounds, compositions and methods
IL220806A0 (en) Method and compositions for enhancing vascular access
IL179241A0 (en) Compositions and methods for bone formation and remodeling
ZA200705196B (en) Compositions and methods for improving kidney function
IL185753A0 (en) Methods and compositions for modulating vascular integrity
IL179917A0 (en) Methods and compositions for modulating hepatocyte growth factor activation
IL184062A0 (en) Visco-supplement composition and methods
IL177104A0 (en) Methods and compositions for modulating angiogenesis
EP1781312A4 (en) FORMULATIONS AND METHOD FOR SATURATION MODULATION
ZA200605722B (en) Composition and method
GB0424051D0 (en) Compounds and compositions
ZA200706038B (en) Visco-supplement composition and methods
EP1812032A4 (en) TISSUE FACTOR COMPOSITION AND RELATED METHODS
AU2011211408B2 (en) Compositions and methods comprising an EGFL7 antagonist for modulating vascular development
HK1094864A (en) Compositions and methods comprising an egfl7 antagonist for modulating vascular development
HK1126675A (en) Compositions and methods for modulating vascular development
GB0428034D0 (en) Compositions and methods
HK1118696A (en) Methods and compositions for enhancing vascular access

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed